ASCO 2025: DecisionDx-Melanoma Provides More Precise Mortality Risk Predictions for Melanoma Patients
Castle’s DecisionDx-Melanoma gene expression profiling (GEP) test can help predict mortality risk among patients with stage I–III cutaneous melanoma (CM), according to research presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.